-

11:16:43 PM

NBIO Stock News

NBIO - Nascent Biotech Inc

01/11/22 8:00 AM

OTC : NBIO

clinical trial

Nascent Successfully Completes 2nd Cohort Dosing in Key Phase 1 Metastatic Brain Cancer Trial

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

07/13/21 8:00 AM

OTC : NBIO

clinical trialcovid-19

Nascent Biotech and Manhattan BioSolutions Announce Promising Prelim/Preclinical Results in BCG-Based COVID-19 Vaccine Research Collaboration

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a biotechnology company pioneering innovative medicines to overcome difficult-to-treat cancers and viral infections, and its collaboration partner, Manhattan

RHEA-AI

positive

06/15/21 8:00 AM

OTC : NBIO

Marble Arch Research Publishes Analyst Research Report on Nascent Biotech

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

06/08/21 8:00 AM

OTC : NBIO

clinical trial

Nascent Biotech Commencing Enrollment of Second Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

05/19/21 8:00 AM

OTC : NBIO

Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent's Pritumumab

Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech ("Nascent" or the "Company") has entered into a license agreement (the "Agreement") with BioRay Pharmaceutical Co Ltd

RHEA-AI

very positive

05/04/21 8:00 AM

OTC : NBIO

Nascent Biotech Continues Anti-Dilution Campaign with Preemptive Settlement of Outstanding Convertible Note

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

04/26/21 8:00 AM

OTC : NBIO

Nascent Biotech Announces Pre-emptive Elimination of Significant Tranche of Convertible Debt

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

03/31/21 8:00 AM

OTC : NBIO

clinical trial

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

03/24/21 8:00 AM

OTC : NBIO

clinical trial

Nascent Biotech Opens Phase 1 Human Trial to Evaluate Pritumumab as Treatment Option for Primary and Metastatic Brain Cancer

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to

RHEA-AI

neutral

03/02/21 8:00 AM

OTC : NBIO

Nascent Biotech Earns US Patent for Crossing Blood-Brain Barrier

Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is excited to

RHEA-AI

positive